The Ubiquitous Chronic Disease Care system significantly reduced HbA1c levels to 7.1% compared to 7.6% in the control group over 12 weeks.
RCT (n=123)
randomized
Yes
Absolute Event Rate: 7.1% vs 7.6%
p-value: p=<0.001
AIMS: The rapidly increasing prevalence of chronic diseases is an important challenge to healthcare systems worldwide. To improve the quality and efficiency of chronic disease care, we investigated the effectiveness and applicability of the Ubiquitous Chronic Disease Care (UCDC) system using cellular phones and the internet for overweight patients with both Type 2 diabetes and hypertension. METHODS: We conducted a randomized, controlled clinical trial over 3 months that included 123 patients at a university hospital and a community public health centre. RESULTS: After 12 weeks, there were significant improvements in HbA(1c) in the intervention group (7.6 +/- 0.9% to 7.1 +/- 0.8%, P < 0.001) compared with the control group (7.4 +/- 0.9% to 7.6 +/- 1.0%, P = 0.03). Furthermore, we observed a significant reduction in systolic and diastolic blood pressure, as well as improvements in total cholesterol, low-density lipoprotein-cholesterol and triglyceride levels in the intervention group. Furthermore, there was a significant increase in adiponectin levels in the intervention group compared with the control group, although high-sensitivity C-reactive protein and interleukin-6 levels did not change in either group. CONCLUSIONS: The novel UCDC system presented in this paper improved multiple metabolic parameters simultaneously in overweight patients with both Type 2 diabetes and hypertension.
Yoo et al. (Mon,) conducted a rct in Type 2 diabetes and hypertension (n=123). Ubiquitous Chronic Disease Care (UCDC) system using cellular phones and the internet vs. Control group was evaluated on HbA(1c) levels (p=<0.001). The Ubiquitous Chronic Disease Care system significantly reduced HbA1c levels to 7.1% compared to 7.6% in the control group over 12 weeks.